|
WO2017053239A1
|
|
Purification of respiratory syncytial virus
|
|
CA2985649A1
|
|
Icp0-mediated enhanced expression system
|
|
WO2015184272A2
|
|
Expression and conformational analysis of engineered influenza hemagglutinin
|
|
AU2015201233A1
|
|
Pharmaceutical compositions containing clostridium difficile toxoids a and b
|
|
WO2014144292A2
|
|
Antibodies against clostridium difficile toxins and methods of using the same
|
|
WO2013184900A2
|
|
Immunogenic compositions and related methods
|
|
AU2013204985A1
|
|
Recombinant flavivirus vaccines
|
|
WO2013116770A1
|
|
Replication-defective flavivirus vaccines and vaccine vectors
|
|
CA2859916A1
|
|
Purification of herpes virus
|
|
CA2896931A1
|
|
Purification of flaviviruses
|
|
AU2012216852A1
|
|
Vaccination against dengue virus infection
|
|
WO2012158639A2
|
|
Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection
|
|
EP2310495A1
|
|
Compositions and methods for the production of alpha-herpesvirus 2
|
|
AU2007317847A1
|
|
Stabilization of vaccines by lyophilization
|
|
AU2006280144A1
|
|
Vaccination against dengue virus infection
|
|
EP1568378A1
|
|
Immunization against Clostridium difficile disease
|
